Trial Profile
Study investigating the efficacy of long-term Lamivudine in preventing Hepatitis B infection in HBsAg-negative recipients of HBcAb+ livers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2015
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 20 Dec 2015 New trial record